Past, Present and Future of Chemodenervation with Botulinum Toxin in the Treatment of Overactive Bladder

Overactive BladderUrinary Tract Infections (UTI)

Onabotulinum toxin A in children with refractory idiopathic overactive bladder: medium-term outcomes

J Pediatr Urol.

Ingham J, Angotti R, Lewis M, Goyal A

doi: 10.1016/j.jpurol.2018.08.007.

Benign Prostatic Hyperplasia (BPH)Lower Urinary Tract SymptomsOveractive Bladder

Use of botulinum toxin for voiding dysfunction

Transl Androl Urol.

Eldred-Evans D, Dasgupta P

doi: 10.21037/tau.2016.12.05.

Overactive Bladder

Effective treatment of ketamine-associated cystitis with botulinum toxin type a injection combined with bladder hydrodistention

J Int Med Res.

Zeng J, Lai H, Zheng D, Zhong L, Huang Z, Wang S, Zou W, Wei L

doi: 10.1177/

Overactive BladderUrinary Incontinence

Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health-Related Quality of Life in Patients with Overactive Bladder

doi: 10.1016/j.juro.2017.05.068.

Overactive Bladder

Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019

J Urol.

Lightner DJ, Gomelsky A, Souter L, Vasavada SP

doi: 10.1097/JU.0000000000000309

Overactive Bladder

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study

Neurourol Urodyn.

Mueller ER, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Stoelzel M, Yoon SJ, Al-Shukri S, Rechberger T, Gratzke C

doi: 10.1002/nau.23919.

Lower Urinary Tract SymptomsOveractive BladderUrinary Tract Infections (UTI)

Treatment of Non-neurogenic Overactive Bladder with OnabotulinumtoxinA: Systematic Review and Meta-analysis of Prospective, Randomized, Placebo-controlled Clinical Trials

Rev Bras Ginecol Obstet.

Arruda RM, Takano CC, Girão MJBC, Haddad JM, Aleixo GF, Castro RA

doi: 10.1055/s-0038-1642631.

Overactive BladderPregnancy and Childbirth

Modifications to Botulinum toxin A delivery in the management of detrusor overactivity recalcitrant to initial injections: a review

World J Urol.

Doherty A, Hennessey DB, Onggo JR, Ranasinghe W, Gani J

doi: 10.1007/s00345-018-2456-7.

Lower Urinary Tract SymptomsOveractive Bladder

Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study

Low Urin Tract Symptoms.

Kato D, Tabuchi H, Uno S

doi: 10.1111/luts.12188.

Related content

Onabotulinum toxin A in children with refractory idiopathic overactive bladder: medium-term outcomes

Use of botulinum toxin for voiding dysfunction

Effective treatment of ketamine-associated cystitis with botulinum toxin type a injection combined with bladder hydrodistention

Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health-Related Quality of Life in Patients with Overactive Bladder

Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study

Treatment of Non-neurogenic Overactive Bladder with OnabotulinumtoxinA: Systematic Review and Meta-analysis of Prospective, Randomized, Placebo-controlled Clinical Trials

Modifications to Botulinum toxin A delivery in the management of detrusor overactivity recalcitrant to initial injections: a review

Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study